Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia

Trovagene, Inc., Continues to Expand NPM1 Licensing Program for Acute Myelogenous Leukemia

[at noodls] – 12/20/2012 Grants Genoptix, Inc. a worldwide, non-exclusive license to incorporate NPM1 into acute myelogenous leukemia research and clinical testing services SAN DIEGO, December 20, 2012 Trovagene, Inc. … more

View todays social media effects on TROV

View the latest stocks trending across Twitter. Click to view dashboard

See who TrovaGene is hiring next, click here to view

Share this post